Olympus endoscope contamination has triggered multiple class action lawsuits and regulatory actions, stemming from bacterial infections linked to duodenoscopes and other endoscopic equipment that weren’t properly cleaned and sterilized between patient uses. Between 2013 and October 2025, at least 37 people died from infections contracted during endoscopic procedures using contaminated Olympus duodenoscopes, with hundreds more suffering serious infections. The outbreak traces back to design flaws in the company’s equipment—particularly the duodenoscope models—that made complete sterilization nearly impossible despite manufacturer protocols, creating what infection control experts call a “superbug” contamination crisis. A specific example underscores the severity: In January 2025, Olympus initiated a Class 1 recall for its MAJ-891 Forceps/Irrigation Plug after identifying approximately 120 injuries and at least one death from contamination.
This device, used during endoscopic procedures, retained bacteria and biological debris that standard hospital sterilization protocols could not eliminate. Patients who underwent routine diagnostic or therapeutic endoscopy procedures—many expecting a quick, low-risk outpatient visit—developed life-threatening infections including multidrug-resistant bacterial infections that proved difficult or impossible to treat with antibiotics. The regulatory response intensified dramatically. In June 2025, the FDA issued an import alert blocking 58 different Olympus endoscope models from entering the United States market. In March 2026, Health Canada took similar action, recalling certain Olympus endoscope components due to incompatibility with automated reprocessing systems, which increased the risk of infection transmission between patients.
Table of Contents
- What Caused the Olympus Endoscope Contamination Crisis?
- The Timeline of Deaths and Injuries from Contaminated Endoscopes
- FDA and Health Canada Regulatory Actions
- Who Is Eligible to File a Claim?
- The Challenge of Proving Causation and the Limitations of Available Remedies
- The Medical and Public Health Impact of Endoscope Contamination
- What the Future Holds for Endoscope Design and Oversight
What Caused the Olympus Endoscope Contamination Crisis?
The contamination problem stems from the design and construction of Olympus duodenoscopes, which are specialized endoscopes used for procedures in the small intestine. These devices have multiple channels, ports, and internal surfaces that, according to medical experts and lawsuits, were nearly impossible to completely sterilize using standard hospital decontamination methods. The devices contained crevices, tight connections, and material compatibility issues that allowed bacteria to survive even after high-temperature steam sterilization or chemical disinfection. Hospital sterilization departments followed Olympus’s published protocols meticulously, yet bacterial cultures from reprocessed duodenoscopes continued to test positive—a critical red flag that the equipment itself, not staff negligence, was the primary problem.
An October 2025 Urgent Field Safety Notice issued by Olympus acknowledged that prior material updates to reprocessing procedures were required for three specific duodenoscope models to address positive bacterial cultures and resulting patient infections. This admission confirmed that the company knew about the sterilization failures but had not immediately recalled the equipment or provided adequate warnings to hospitals. The superbug aspect refers specifically to multidrug-resistant organisms such as carbapenem-resistant Enterobacteriaceae (CRE) that were isolated from patients and traced back to contaminated equipment. These infections are called “superbugs” because they resist multiple classes of antibiotics, making them particularly dangerous and expensive to treat.
The Timeline of Deaths and Injuries from Contaminated Endoscopes
From 2013 through 2024, documented deaths linked to contaminated Olympus duodenoscope infections reached at least 35, with the actual number likely higher due to underreporting and delayed diagnosis. Between 2024 and October 2025, the company received reports of an additional 2 deaths and 5 serious injuries specifically from infections transmitted via TJF duodenoscope models. The pattern reveals that despite earlier recalls and warnings, Olympus continued producing and distributing equipment that posed an infection risk to patients. A critical limitation in tracking the true scope of harm is that infection sources are often difficult to pinpoint after the fact.
Patients infected during endoscopy may not develop symptoms for days or weeks, making the causal connection to the procedure harder to establish. Some hospitals did not routinely report infections, and some infected patients sought treatment at different facilities, obscuring the pattern. Additionally, elderly and immunocompromised patients—populations most likely to undergo endoscopic procedures—face higher mortality rates from any infection, meaning some deaths attributed to the underlying medical condition may have actually been triggered by contamination. The January 2025 MAJ-891 recall represented a watershed moment, with 120 reported injuries and at least 1 death directly tied to this single accessory component. This concentrated cluster of harm within a brief timeframe prompted more aggressive FDA and Health Canada action.
FDA and Health Canada Regulatory Actions
On June 24, 2025, the FDA took the extraordinary step of issuing an import alert that effectively blocked 58 Olympus endoscope models from entering the United States. Import alerts are serious regulatory tools used only when there is a substantial public health threat; they prevent products from clearing customs and reaching hospitals or surgery centers. The scope of the alert—covering 58 distinct models—demonstrates that the contamination issue was not limited to one or two products but represented a systemic problem with Olympus’s endoscope design and quality control.
In March 2026, Health Canada issued its own recall of certain Olympus endoscope components, citing incompatibility with automated reprocessing systems commonly used in Canadian hospitals. Automated reprocessing machines are designed to clean and disinfect equipment using standardized cycles, but if the equipment design itself creates areas where these machines cannot reach or adequately treat, the system breaks down. This regulatory action signaled that the problem extended across North America and affected even equipment already distributed and in use. One important example: a hospital that had been using a specific Olympus duodenoscope model for several years and following all manufacturer instructions discovered, following the FDA import alert, that it could no longer safely use that equipment and had no clear path to replace it with newer models in the short term, leaving some procedures temporarily unavailable to patients.
Who Is Eligible to File a Claim?
Patients who underwent endoscopic procedures using contaminated Olympus equipment and subsequently developed infections are the primary class members eligible to file claims. This includes individuals who underwent upper endoscopy (EGD), colonoscopy, endoscopic retrograde cholangiopancreatography (ERCP), or other procedures using Olympus duodenoscopes between 2013 and the present. The class action lawsuits do not require proof that the infection was fatal—serious infections requiring hospitalization, prolonged antibiotic treatment, or resulting in permanent health complications can all support a claim.
A comparison with other medical device litigation illustrates the challenge: Unlike some product liability cases where a single injury is obvious at the time of purchase (e.g., a defective implant), endoscope contamination injuries are latent and may only become apparent days or weeks after the procedure when infection symptoms emerge. Affected patients must often piece together their medical records, procedure dates, endoscope models used, and subsequent infection diagnoses. Some hospitals did not document which specific Olympus model was used for each procedure, complicating proof of exposure. Eligible claimants typically need to provide: medical records documenting the endoscopic procedure and the date it occurred; evidence of subsequent infection diagnosis; hospital or clinic records identifying the specific endoscope model used (when available); and any documentation of treatment, hospitalization, or antibiotic therapy related to the infection.
The Challenge of Proving Causation and the Limitations of Available Remedies
A significant limitation in endoscope contamination claims is the challenge of definitively proving that the specific procedure caused the infection, rather than an infection acquired elsewhere. Infections can spread through multiple pathways in a hospital setting, and patients may have been exposed to infectious agents during the same hospitalization from other sources. Defense arguments often point to alternative sources of infection, requiring claimants to work with medical experts to establish that the infection’s timing, organism type, and clinical presentation make contamination via the endoscope the most likely source. Another warning: even when infection is documented, proving that it resulted from equipment contamination rather than improper reprocessing by hospital staff can be contentious.
Olympus has argued in litigation that some infections resulted from hospital failures to follow sterilization protocols, rather than from inherent design flaws in the equipment. However, the October 2025 Urgent Field Safety Notice and prior admissions by the company that design changes to reprocessing materials were needed have undermined these arguments, effectively conceding that the equipment itself was the primary issue. Damages in these lawsuits typically cover medical expenses related to infection treatment, lost wages, pain and suffering, and, in fatal cases, wrongful death benefits. However, settlement amounts vary significantly depending on the severity of harm, jurisdiction, and the specific evidence presented.
The Medical and Public Health Impact of Endoscope Contamination
Healthcare facilities across the United States and Canada faced unprecedented challenges following the FDA import alert and recalls. Hospitals that had invested in Olympus duodenoscopes suddenly could not receive replacement parts or new units, forcing them to transfer patients to other facilities for procedures, reduce procedure schedules, or invest in equipment from competing manufacturers. This cascading effect disrupted routine medical care for tens of thousands of patients waiting for diagnostic and therapeutic endoscopic procedures.
From a public health perspective, the outbreak revealed gaps in device surveillance and post-market monitoring. Infections linked to contaminated endoscopes were being reported to hospitals and manufacturers, but coordination between hospitals and regulatory agencies was insufficient to rapidly identify the pattern and trigger swift action. The involvement of multidrug-resistant organisms (superbugs) made the public health threat particularly acute, as infected patients could spread resistant bacteria to family members and other hospital patients, creating secondary transmission chains.
What the Future Holds for Endoscope Design and Oversight
The Olympus endoscope crisis has prompted manufacturers to revisit design standards, with a focus on eliminating tight crevices, improving material compatibility with standard sterilization methods, and enhancing the accessibility of internal channels to cleaning and disinfection tools. Regulatory agencies, including the FDA, are now scrutinizing endoscope designs more carefully during the approval process, with greater emphasis on sterilization validation data.
Looking forward, the medical device industry is likely to see increased investment in new sterilization technologies and alternative device designs that are inherently less prone to contamination. However, this transition will take years, and older equipment will remain in use during the interim. Hospitals and patients should expect ongoing recalls and warnings as regulatory agencies continue to identify contamination risks in devices already in the field.
You Might Also Like
- Zetia Vytorin Cholesterol Antitrust Class Action Settlement
- Zetia Cholesterol Drug Antitrust Class Action Settlement
- Wright Hip Implant Metallosis Class Action
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: